Check for updates

RESEARCH ARTICLE

FAM129B is a novel regulator of Wnt/ β -catenin signal transduction in melanoma cells [version 1; peer review: 1 approved, 1 approved with reservations]

William Conrad^{1,2}, Michael B Major^{1,3}, Michele A Cleary^{4,5}, Marc Ferrer^{6,7}, Brian Roberts^{4,8}, Shane Marine⁹, Namjin Chung^{4,10}, William T Arthur^{4,11}, Andy J Chien^{12,13}, Jason D Berndt^{1,2,13}, Randall T Moon^{1,2,13}

¹The Howard Hughes Medical Institute, Seattle WA, 98195, USA

²Department of Pharmacology, University of Washington School of Medicine, Seattle WA, 98195, USA

³Department of Cell Biology and Physiology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill NC, 27599-7295, USA

⁴Rosetta Inpharmatics, LLC, Merck & Co Inc., Seattle WA, 98109, USA

⁵Merck & Co., Inc., West Point PA, 19486, USA

⁶Department of Automated Biotechnology, Merck, North Wales PA, 19454, USA

⁷NCATS/NIH, Rockville MD, 20850, USA

⁸Hudson Alpha Institute for Biotechnology, Huntsville AL, 35806, USA

⁹Department of Screening and Protein Sciences, Merck Research Laboratories, North Wales PA, 19454, USA

¹⁰Bristol-Myers Squibb Company, Applied Genomics, Princeton NJ, 08543, USA

¹¹Seattle Genetics, Bothell WA, 98021, USA

¹²Division of Dermatology, Department of Medicine, University of Washington, Seattle WA, 98195, USA

¹³The Institute for Stem Cell and Regenerative Medicine, Seattle WA, 98109, USA

v1 First published: 31 May 2013, 2:134
<https://doi.org/10.12688/f1000research.2-134.v1>

Latest published: 10 Oct 2013, 2:134
<https://doi.org/10.12688/f1000research.2-134.v2>

Abstract

The inability of targeted BRAF inhibitors to produce long-lasting improvement in the clinical outcome of melanoma highlights a need to identify additional approaches to inhibit melanoma growth. Recent studies have shown that activation of the Wnt/ β -catenin pathway decreases tumor growth and cooperates with ERK/MAPK pathway inhibitors to promote apoptosis in melanoma. Therefore, the identification of Wnt/ β -catenin regulators may advance the development of new approaches to treat this disease. In order to move towards this goal we performed a large scale small-interfering RNA (siRNA) screen for regulators of β -catenin activated reporter activity in human HT1080 fibrosarcoma cells. Integrating large scale siRNA screen data with phosphoproteomic data and bioinformatics enrichment identified a protein, FAM129B, as a potential regulator of Wnt/ β -catenin signaling. Functionally, we demonstrated that siRNA-mediated knockdown of FAM129B in A375 and A2058 melanoma cell lines inhibits WNT3A-mediated activation of a β -catenin-responsive luciferase reporter and inhibits expression of the endogenous Wnt/ β -

Open Peer Review

Approval Status

	1	2
version 2		
(update)
10 Oct 2013
version 1		
31 May 2013

1. **Madelon Maurice**, University Medical Center
 Utrecht, Utrecht, The Netherlands

2. **Udayan Apte**, University of Kansas Medical
 Center, Kansas City, KS, USA

Any reports and responses or comments on the article can be found at the end of the article.

catenin target gene, AXIN2. We also demonstrate that FAM129B knockdown inhibits apoptosis in melanoma cells treated with WNT3A. These experiments support a role for FAM129B in linking Wnt/ β -catenin signaling to apoptosis in melanoma.

Keywords

apoptosis, FAM129B, Wnt/ β -catenin, siRNA, melanoma, tumor

Corresponding author: Randall T Moon (rtmoon@u.washington.edu)

Competing interests: No competing interests were disclosed.

Grant information: WC was supported by a Pharmaceutical Sciences Training grant (5T32GM007750). AJC is funded by the NIH/National Cancer Institute (NCI) (K08CA128565).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2013 Conrad W *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Conrad W, Major MB, Cleary MA *et al.* **FAM129B is a novel regulator of Wnt/ β -catenin signal transduction in melanoma cells [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2013, 2:134 <https://doi.org/10.12688/f1000research.2-134.v1>

First published: 31 May 2013, 2:134 <https://doi.org/10.12688/f1000research.2-134.v1>

Introduction

The incidence of melanoma continues to rise across the U.S. at a rate faster than any other cancer¹. Malignant melanoma has a poor prognosis with a 5-year survival rate of only 15%². The recently approved therapeutic, vemurafenib, extends median patient survival by 7 months³⁻⁶. This major advance raises expectations that even greater rates of survival might be attainable with combination therapies.

Activation of the Wnt/ β -catenin pathway decreases tumor growth and cooperates with ERK/MAPK pathway inhibitors to promote apoptosis in melanoma^{1,7-13}. Analysis of melanoma tumor samples show a positive correlation between nuclear β -catenin staining and decreased tumor depth, increased patient survival and increased time to metastasis¹⁴⁻¹⁷. Moreover, treatment with WNT3A-containing conditioned media or stable overexpression of WNT3A in mouse B16 or human A375 melanoma cells reduces cell number *in vitro*¹⁰⁻¹². Allografts of mouse B16 or mouse xenografts of human A375 cells overexpressing WNT3A decrease tumor size compared to control^{17,18}. Recently, we found that activation of Wnt/ β -catenin signaling concurrent with the inhibition of the ERK/MAPK pathway synergistically elevates apoptosis in a subset of *BRAF*- and *NRAS*-mutant cultured human melanoma cells^{18,19}. Given the interaction between Wnt/ β -catenin signaling and pathways known to be critical for melanoma pathogenesis, the identification of Wnt/ β -catenin regulators might prove to be informative in developing novel approaches to treat this disease.

In the present study, we identify novel regulators of Wnt/ β -catenin signaling in melanoma by performing a large-scale small-interfering RNA (siRNA) screen of a Wnt/ β -catenin responsive reporter in human HT1080 fibrosarcoma cells, and by identifying siRNA targets that are also regulated by ERK/MAPK signaling and that have been previously associated with melanoma. By integrating these three approaches, we identified FAM129B as a potential regulator of Wnt/ β -catenin signaling. FAM129B is a 746 amino acid protein that contains an amino-terminal pleckstrin homology (PH) domain and a differentially phosphorylated carboxy-terminal region²⁰. FAM129B is known to inhibit TNF α -dependent apoptosis in HeLa cells²¹. FAM129B is expressed in melanoma and promotes tumor cell invasion into collagen matrices in an ERK/MAPK phosphorylation-dependent manner²⁰. In the present study we demonstrate that FAM129B promotes Wnt/ β -catenin signal transduction in melanoma and that reducing levels of FAM129B with siRNA reduces the ability of WNT3A to increase apoptosis in melanoma cells.

Results

Phosphoproteomic and siRNA screens identify FAM129B as a regulator of Wnt/ β -catenin signaling

In order to identify novel regulators of Wnt/ β -catenin signaling, we performed a siRNA screen. We used HT1080 cells stably transduced with a luciferase reporter of β -catenin-mediated transcription (BAR)²². We screened 28,044 pools of siRNAs. 19,490 gene products were targeted by one or more siRNA pool. Cells were transfected with siRNAs and treated with WNT3A-conditioned media to activate the reporter. BAR activity was normalized to the activity of *Renilla* luciferase driven by the constitutive TK promoter to control for total cell number. siRNAs targeting positive control proteins such as the known Wnt/ β -catenin inhibitor, *AXIN2*, modulated BAR activity by

at least 2.0 fold with a p-value less than 0.01 (Figure 1b). Using this as a criterion, we found that 10,215 siRNA pools regulated BAR activity. Of the 19,490 gene products targeted by one or more siRNA in our screen, we identified 5189 gene products for which every given siRNA significantly regulated BAR activity (Data File 1).

To refine the results of our large-scale siRNA screen, we performed an integrative analysis of our siRNA screen regulators by cross-referencing these regulators with a list of genes previously identified in melanoma, and a list of gene products phosphorylated downstream of MEK and ERK in melanoma. First, we identified 12 proteins in common between the siRNA and phosphoproteomic screens (Figure 1a and Data File 3a). Next, we generated a list of melanoma-associated genes using a custom biopython script (Data File 2 and Query Script). We identified 745 melanoma-associated genes by querying the NCBI gene database. Of these, one gene (*FAM129B*) encoded a protein that was differentially phosphorylated following MEK inhibition (Figure 1 and Data File 3a) and 123 were gene targets of siRNA pools that regulated Wnt/ β -catenin signaling (Figure 1b, and Data File 3b). Finally, we discovered *FAM129B* as the only melanoma-associated gene that both modulated Wnt/ β -catenin signaling and was phosphorylated following MEK activation, (Figure 1b and Data File 3a).

Data sets and query script used in identifying FAM129B as a putative regulator of Wnt/ β -catenin signaling using a largescale siRNA screen integrated with phosphoproteomic and bioinformatic analyses

5 Data Files

<http://dx.doi.org/10.6084/m9.figshare.705154>

Validation of FAM129B as a regulator of Wnt/ β -catenin signaling

The siRNA screen suggested that FAM129B is a regulator of Wnt/ β -catenin signaling. In order to confirm this possibility, we designed three independent siRNAs targeting *FAM129B*. First, we confirmed that all three siRNAs inhibit expression of FAM129B protein in HT1080 fibrosarcoma, A2058 melanoma and A375 melanoma cells (Figure 2a). Next, we asked whether the siRNAs inhibited the ability of WNT3A to activate BAR. Indeed, we found that each FAM129B siRNA reduced the ability of WNT3A to activate BAR in all three cell lines (Figure 2b). We also tested whether FAM129B siRNAs reduce the ability of WNT3A to elevate expression of the endogenous β -catenin target gene, *AXIN2*. Similar to inhibition of BAR, *FAM129B* siRNAs significantly reduced levels of *AXIN2* transcript relative to control siRNA (Figure 2c). From these data, we conclude that *FAM129B* knockdown inhibits the ability of WNT3A to promote β -catenin mediated transcriptional activation.

While FAM129B modulates Wnt/ β -catenin signaling in the above assays, these experiments do not rule out the formal possibility that reducing levels of FAM129B might affect other signaling pathways. We therefore generated A375 melanoma cell lines stably transduced with a luciferase-based reporter to the TNF α pathway. We then transfected cells with *FAM129B* siRNAs and stimulated the reporters with cognate ligands. While *FAM129B* siRNAs inhibit

Figure 1. FAM129B is identified as a putative regulator of Wnt/ β -catenin signaling using large-scale siRNA screen integrated with phosphoproteomic and bioinformatic analyses. (a) Volcano plots depicting siRNA screen hits overlaid with phosphoproteomic data or bioinformatic data (left panel). Median effect of each siRNA treatment as a percent of control siRNAs were plotted against the p-value of that treatment. If, for a given gene, all siRNAs targeting that gene showed a twofold change in normalized reporter activity and a p-value <0.01 , that gene was classified as a hit. This screen identified 5,189 gene products as hits, which are depicted in dark grey. Overlapping phosphoproteomic data from Old WM *et al.* (2009)¹⁵ are depicted in light grey. The known regulator of Wnt/ β -catenin signaling, *AXIN2*, is indicated, as is FAM129B (right panel). Data plot is the same as the left panel with melanoma-associated genes plotted in light grey instead. (b) Venn diagram depicting overlaps between phosphoproteomic dataset, siRNA screen and melanoma-associated genes. 12 protein targets overlap between the phosphoproteomic hits and the siRNA screen, 1 protein target overlaps between the phosphoproteomic hits and melanoma-associated protein targets, and 123 proteins overlap between the siRNA screen hits and melanoma associated protein targets. Only FAM129B overlaps with all three datasets.

Figure 2. FAM129B positively regulates Wnt/ β -catenin signal transduction in a panel of three cell lines. (a) Immunoblots show three independent siRNAs reduce steady-state levels of FAM129B following 72 hr treatment with 20 nM siRNA. The beta-tubulin immunoblot serves as a control. Three independent siRNAs targeting *FAM129B* inhibit FAM129B expression in HT1080 (left), A2058 (middle), and A375 cells (right). (b) *FAM129B* siRNA inhibit WNT3A-dependent luciferase reporter activity (BAR reporter) normalized to constitutively expressed *Renilla* luciferase in HT1080 (left), A2058 (middle), and A375 cells (right). (c) *FAM129B* siRNA inhibit Wnt-dependent *AXIN2* expression in HT1080 (left), A2058 (middle), and A375 cells (right) relative to beta-actin mRNA expression by qPCR. Columns and error bars represent mean and SEM, respectively. Data are representative of at least three separate biological replicates. * $p < 0.05$ by unpaired, two-tailed T-test.

activation of the BAR reporter by WNT3A across a wide range of doses (Figure 3a), *FAM129B* siRNA has only negligible effects on TNF α -dependent NF κ B reporter activity (Figure 3b). While this result does not allow the conclusion that FAM129B functions solely as a modulator of β -catenin signaling, this result does suggest that FAM129B is not required for activation of all pathways.

FAM129B regulates WNT3A-mediated apoptosis in A375 melanoma cells

The combined treatment with WNT3A protein and compounds that inhibit ERK/MAPK signaling synergizes to induce robust apoptosis in cultured melanoma cells^{18,19}. If FAM129B is required for Wnt/ β -catenin signaling, then FAM129B loss of function should inhibit this synergy. We monitored apoptosis in A375 melanoma cells by western blot for cleaved caspase-3 and immunofluorescence staining for TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling). As previously reported^{18,19}, A375 cells treated with control siRNA and the combination of WNT3A and PLX4720 exhibit robust levels of cleaved caspase-3 (Figure 4a). siRNA mediated knockdown of *FAM129B* decreases the levels of cleaved caspase-3 in response to WNT3A siRNA (Figure 4a–4c). Moreover, when measuring WNT and PLX4720-dependent apoptosis by TUNEL staining, we found that siRNA mediated FAM129B knockdown reduced the number of TUNEL positive cells as compared to control siRNAs. Collectively, these results show that FAM129B is required for the synergy between Wnt3A and PLX4720 to induce melanoma apoptosis.

Data showing positive regulation of Wnt/ β -catenin signal transduction by FAM129B siRNA using transcriptional reporter assay, target gene expression, and apoptosis assay

7 Data Files

<http://dx.doi.org/10.6084/m9.figshare.705153>

Discussion

We combined phosphoproteomics and siRNA screening to identify novel regulators of Wnt/ β -catenin signaling in human melanoma. We focused on FAM129B, a previously identified protein that has not formerly been linked to Wnt/ β -catenin signaling. Using independent siRNAs, we confirmed that *FAM129B* is required for Wnt3A to activate a β -catenin dependent reporter and reduces the ability of Wnt3A to enhance the expression of the β -catenin target gene *AXIN2*. We demonstrated that loss of function of FAM129B inhibits the apoptosis of melanoma cells induced by the combined treatment with WNT3A and PLX4720.

FAM129B siRNAs suppress apoptosis in melanoma cells treated with WNT3A and PLX4720. This result was surprising given that the transfection of *FAM129B* siRNA in HeLa cells promotes increased apoptosis in response to TNF α and cyclohexamide²¹. The discrepancy between the ability of *FAM129B* siRNAs to suppress Wnt-dependent apoptosis in melanoma and the ability of these siRNA to promote TNF α -mediated apoptosis in HeLa remains unresolved, although it does suggest that FAM129B may function in a manner that is dependent on cellular context. Alternatively, the differences in apoptotic response with FAM129B loss of function

may merely reflect the regulation of Wnt/ β -catenin signaling in these two cell types. Uncovering the underlying roles of FAM129B in the cell may well illuminate how FAM129B exerts these opposing effects on apoptosis in response to different stimuli. Future studies should probe the role, if any, of TNF α /NF κ B in melanoma apoptosis and the cross-talk between Wnt/ β -catenin and TNF α /NF κ B signaling in cell lines, such as HeLa, that respond to TNF α by apoptosis.

Materials and methods

Plasmids

Detailed information on the β -catenin activated reporter plasmid (pBARLS) has been previously described^{23,24}. Briefly, the reporters are generated from lentiviral plasmids that contain 12 TCF/LEF binding sites (5'-AGATCAAAGG-3') or Nuclear Factor Kappa B (5'-GGGAATTTCC-3') signaling pathways separated by distinct 5-base pair linkers upstream of a minimal promoter and the firefly luciferase open reading frame. The reporters also contain a separate PGK (phosphoglycerate kinase) promoter that constitutively drives the expression of a puromycin resistance gene for mammalian cell selection. These reporters were generated by Travis L. Biechele in the lab of Randall T Moon as previously published^{23,24}.

Cell lines and cell culture

Human A375 and A2058 cells were a generous gift from Cassian Yee (Fred Hutchinson Cancer Research Institute, Seattle, WA). HT1080 cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Stable reporter lines were generated as previously described²². Cell lines were cultured in a Thermo Forma steri-cult humidified incubator (#3310, Thermo Scientific, Rockford, IL) at 37°C and 5% CO₂. All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM, #11965–084 Invitrogen, St. Louis, MO) containing 10% fetal bovine serum and 1% Penicillin/Streptomycin (Invitrogen, Grand Island, NY), except A375 cells, which were grown in DMEM containing 5% FBS and 1% P/S.

Control (LCM) and WNT3A-conditioned media (WNT3A CM) used to activate the Wnt/ β -catenin signaling pathway were prepared as previously described²⁵. To monitor reporter activity and transcript activity, cells were treated with 10% WNT3A CM or LCM overnight before proceeding to subsequent assays. To monitor effects on apoptosis, cells were treated with 1% LCM or WNT3A and DMSO (Sigma St. Louis, MO, product 472301) or 2 μ M PLX4720 (Symanis, Timaru New Zealand SY-PLX4720).

Large-scale siRNA screen

The large-scale siRNA screen was performed as previously described²⁶, with minor modifications. Briefly, HT1080 cells stably transduced with BAR firefly luciferase and *Renilla* luciferase lentiviruses were reverse-transfected in 1536-well plates, with a final concentration of pooled siRNA at 25 nM. 48 hours after reverse transfection, cells were treated with WNT3A-conditioned media. Following overnight incubation, β -catenin dependent transcription was measured by assaying firefly luciferase activity and normalized by monitoring constitutively expressed *Renilla* luciferase activity as described in the Promega Dual glo luciferase assay system technical manual (Promega, Madison WI). All siRNAs were designed with a proprietary algorithm²⁷.

Figure 3. *FAM129B* siRNA regulate Wnt-dependent transcriptional reporter, but not $TNF\alpha/NF\kappa B$ dependent reporter. (a, left panel) pooled *FAM129B* siRNAs inhibit Wnt-dependent BAR reporter activity over a wide range of doses. Increasing doses of WNT3A d increases activation of the BAR reporter (normalized to constitutive *Renilla* luciferase in control treated cells). WNT3A does not activate the reporter in the presence of *FAM129B* or *CTNNB1* siRNAs. (Right panel) A375 cells were treated with siRNAs as indicated and treated with an EC50 dose of WNT3A (50 ng/ml). All *FAM129B* siRNA and positive control *CTNNB1* siRNA inhibit Wnt-dependent BAR reporter activity. (b) The same experiment was carried out as in (a, left panel) in A375 lines $TNF\alpha/NF\kappa B$ reporter. Data in the left panel indicate dose-dependent activation of the $NF\kappa B$ reporter by $TNF\alpha$. However, *FAM129B* siRNAs do not inhibit the activation of the $TNF\alpha/NF\kappa B$ reporter. (Right panel) *FAM129B* siRNA do not regulate activity of the $NF\kappa B$ reporter activated by 1.5 ng $TNF\alpha$ /ml in A375 cells. High dose $TNF\alpha$ (10 ng/ml) does differentially activate the reporter. Data represent 3 separate biological replicates. * $p < 0.05$ by unpaired, two-tailed T-test.

Figure 4. FAM129B positively regulates Wnt/ β -catenin-dependent apoptosis in A375 melanoma. (a) *FAM129B* siRNA inhibits Wnt-dependent apoptosis as monitored by cleaved caspase-3 immunoblot. A375 cells were treated with pooled control, pooled *FAM129B* siRNA, or *CTNNB1* siRNA as indicated for 48 hr. Cells were subsequently treated with DMSO or 2 μ M PLX4720, and L-conditioned or WNT3A-conditioned media for 24 hr as indicated. Knockdown of *FAM129B* was monitored by *FAM129B* immunoblot, inhibition of ERK/MAPK signaling by phospho-ERK immunoblot, and total ERK was used as normalization. Relative levels of cleaved caspase-3 were quantitated by normalizing cleaved caspase-3 pixel density to ERK1/2 for each condition relative to the maximum cleaved caspase-3 level. Data are representative of at least 3 biological replicates. *FAM129B* siRNA inhibit cleaved caspase-3 levels to between 16 and 41% of maximum. (b) *FAM129B* siRNA inhibits Wnt-dependent apoptosis as quantified by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) immunofluorescence (IF). A375 melanoma cells were treated as above, fixed and stained using TUNEL. Percent TUNEL positive cells calculated as a percent of DAPI positive cells. (c) Representative immunofluorescence of A375 cells treated with the indicated conditions. TUNEL staining is depicted in red and DAPI staining is depicted in blue. Columns and error bars represent the mean and SEM of three separate biological replicates. * $p < 0.05$ by student's T-test.

siRNA transfection and low throughput reporter assays

Approximately 200,000 A375, A2058, or HT1080 cells (as estimated by hemocytometer counts) were reverse transfected at a final dose of 20 nM siRNA in 6-well format using 5 μ l RNAi max/well (Invitrogen, Grand Island, NY). Medium GC universal stealth control siRNA was used as a negative control (Cat. No. 12935–112, Invitrogen, Grand Island, NY). Invitrogen's stealth siRNA targeting *FAM129B* were designed using the BLOCK-iT RNAi designer and are described below. The sequence for “FAM129B A” is UCACGACAUGAACCGAACGUGCAU. The sequence for “FAM129B B” is ACUGAGGUGCGAGAUGUCUUCUUA. The sequence for “FAM129B C” is CAGCAGCGAUUUGAUGUGUCCAGCA. As a positive control for inhibition of Wnt/ β -catenin signal transduction by siRNA, we used silencer select siRNA targeting *CTNNB1* with the sequence GGUGGUGGUAAUAAGGCUTT (Invitrogen, Grand Island, NY).

24 hr after siRNA transfection, cells were plated in 96-well plates at a density of 20,000 cells/well. Twenty-four hours after plating, cells were treated with the indicated conditions, and luciferase activity was measured 15 hours later with a Dual-Luciferase Reporter Assay kit (Promega, Madison, WI) and an Envision multilabel plate reader (PerkinElmer, Waltham, MA) according to the manufacturer's suggestions.

qPCR

24 hr after siRNA transfection, cells were split into a 12-well cluster plate at approximately 50% confluency. 24 hr later, cells were treated with WNT3A- or L-conditioned media. After overnight treatment, RNA was isolated using Trizol reagent according to the manufacturer's instructions (Invitrogen). 1 μ g of RNA was reverse transcribed using Fermentas' RevertAid M-MuLV Reverse Transcriptase (Fermentas, Glen Burnie, MD). QPCR was performed on a Lightcycler 480 (Roche, Indianapolis, IN) using Lightcycler 480 DNA SYBR Green 1 master mix (04707516001 Roche, Indianapolis, IN). The following primers were used for qPCR: “*AXIN2* F” CTCCCCACCTTGAATGAAGA and “*AXIN2* R” TGGCTGGTGCAAAGACATAG; and, “*ACTB* F” AGAGCAAGAGAGGCATCCTC and “*ACTB* R” CTCAAACATGATCTGGGTCA.

Cell lysis and immunoblotting

To test for siRNA knockdown, replicate cell lysates from low throughput reporter assays were pooled and treated with 10 $\times$ RIPA lysis buffer (500 mM Tris, pH 7.5, 1.5 M NaCl, 10 mM EDTA, 10% Igepal CA-630, 1% SDS, and 2% sodium deoxycholate all purchased from Sigma, St. Louis, MO). For monitoring cleaved caspase-3, 90% confluent 12-well plates were treated for 24-hr with the indicated conditions described in the “cell lines and cell culture” section. Media were collected and cells were rinsed once (gently) with PBS. Cells were lysed on-plate in 100 μ l 1 $\times$ RIPA buffer containing protease and phosphatase inhibitors (Complete EDTA-free and PhoStop by Roche, Indianapolis, IN). Cells were disrupted by scraping of a 1000 μ l pipette tip against the plate. Apoptotic cells present in the media and PBS wash were centrifuged at 300 g, rinsed once with PBS, and lysed with the RIPA buffer collected from the plate lysis. Cell lysates were cleared by centrifugation at 20,000 g at 4°C for 10 minutes. Protein lysates were separated by SDS-PAGE using NuPAGE 4%–12% Bis-Tris gels (NP0336BOX, Invitrogen, Grand Island, NY) in MES buffer, and transferred onto

a nitrocellulose membrane (162–0115, Bio-Rad, Hercules, CA) using IDEA scientific GENIE transfer apparatuses (Idea Scientific, Minneapolis, MN). Blots were probed using polyclonal rabbit anti FAM129B (#HPA023261 Sigma, St. Louis, MO), monoclonal mouse anti Tubulin (#T7816 Sigma, St. Louis, MO), monoclonal mouse anti β -catenin (C2206 Sigma, St. Louis, MO), polyclonal Rabbit anti cleaved-caspase-3 (#9661 cell signaling), Rabbit anti ERK1/2 (#9102 cell signaling, Danvers, MA), Rabbit anti phospho ERK1/2 (#9211 cell signaling, Danvers, MA).

TUNEL immunofluorescence

Glass coverslips were coated with poly-L-lysine in a 24-well dish, rinsed with PBS, and dried. Following reverse transfection as described above, cells were seeded at a density to achieve 90 to 100% confluency at harvest. Twenty-four hours after seeding, cells were treated with the indicated conditions and incubated for 24 hours with the indicated conditions as described above in the “cell lines and cell culture” section. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed using an *in situ* cell death detection kit (Roche, Indianapolis, IN). Briefly, the medium was gently aspirated, to keep apoptotic bodies on the slide, and cells were fixed in 4% paraformaldehyde for 1 hour at room temperature. Cells were gently rinsed twice with PBS and permeabilized with 0.1% Triton X-100 (Sigma, St. Louis, MO) in 0.1% sodium citrate (Sigma, St. Louis, MO) for 2 min on ice. Cells were rinsed twice with PBS and 40 ml of TUNEL reaction mixture was added directly on top of the slide; cells were incubated for 1 hour at 37°C in a humidified incubator. Slips were rinsed three times with PBS and mounted on Superfrost Plus glass slides with ProLong Gold anti-fade mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, Grand Island, NY). Images were obtained on a Nikon TiE inverted wide-field high-resolution microscope. DAPI and TUNEL positive nuclei were quantified blinded for 5 fields per slide using NIS elements (Nikon Instruments Inc, Melville, NY).

Statistics

Except where indicated, a student's t test was used to assess the statistical significance of the differences between the different groups; a p value of <0.05 was considered significant.

Author contributions

WC, RTM, AC and JB conceived the study. MF, SM, and NC automated the large-scale screen. MBM, MAC, BR, and WTA designed and carried out the large scale screen. WC carried out the research in melanoma cells and identified melanoma-associated genes. WC prepared the first draft of the manuscript. AC, JB, and RTM contributed to the experimental design and preparation of the manuscript. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Competing interests

No competing interests were disclosed.

Grant information

WC was supported by a Pharmaceutical Sciences Training grant (5T32GM007750). AJC is funded by the NIH/National Cancer Institute (NCI) (K08CA128565).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We thank Cassian Yee for contributing the A375 and A2058 cells. Thanks to Travis Biechele for providing the beta-catenin reporter constructs. MC and WA were employees of Rosetta/Merck. JB

is an associate of the Howard Hughes Medical Institute. RTM is an investigator of the Howard Hughes Medical Institute. We are indebted to these funding agencies for their continued support of our work. The contents of this manuscript are the sole responsibility of the authors and do not necessarily represent the official views of the NIAMS, NCI, NIH, or the Howard Hughes Medical Institute.

References

- Kageshita T, Hamby CV, Ishihara T, *et al.*: **Loss of beta-catenin expression associated with disease progression in malignant melanoma.** *Br J Dermatol.* 2001; **145**(2): 210–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kohler BA, Ward E, McCarthy BJ, *et al.*: **Annual Report to the Nation on the Status of Cancer, 1975–2007, Featuring Tumors of the Brain and Other Nervous System.** *J Natl Cancer Inst.* 2011; **103**(9): 714–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- American Cancer Society. Cancer Facts & Figures 2011 [Internet],** American Cancer Society; 2011.
[Reference Source](#)
- Chapman PB, Hauschild A, Robert C, *et al.*: **Improved survival with vemurafenib in melanoma with BRAF V600E mutation.** *N Engl J Med.* 2011; **364**(26): 2507–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Flaherty KT, Puzanov I, Kim KB, *et al.*: **Inhibition of mutated, activated BRAF in metastatic melanoma.** *N Engl J Med.* 2010; **363**(9): 809–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sosman JA, Kim KB, Schuchter L, *et al.*: **Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.** *N Engl J Med.* 2012; **366**(8): 707–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sosman JA, Kim KB, Schuchter L, *et al.*: **Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.** *N Engl J Med.* 2012; **366**(8): 707–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Maelandsmo GM, Holm R, Nesland JM, *et al.*: **Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.** *Clin Cancer Res.* 2003; **9**(9): 3383–8.
[PubMed Abstract](#)
- Bachmann IM, Straume O, Puntervoll HE, *et al.*: **Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.** *Clin Cancer Res.* 2005; **11**(24 Pt 1): 8606–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chien AJ, Moore EC, Lonsdorf AS, *et al.*: **Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.** *Proc Natl Acad Sci U S A.* 2009; **106**(4): 1193–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Biechele TL, Camp ND, Fass DM, *et al.*: **Chemical-genetic screen identifies riluzole as an enhancer of Wnt/beta-catenin signaling in melanoma.** *Chem Biol.* 2010; **17**(11): 1177–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Biechele TL, Kulikaukas RM, Toroni RA, *et al.*: **Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.** *Sci Signal.* 2012; **5**(206): ra3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Conrad WH, Swift RD, Biechele TL, *et al.*: **Regulating the response to targeted MEK inhibition in melanoma: Enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/beta-catenin activation.** *Cell Cycle.* 2012; **11**(20): 3724–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kageshita T, Hamby CV, Ishihara T, *et al.*: **Loss of beta-catenin expression associated with disease progression in malignant melanoma.** *Br J Dermatol.* 2001; **145**(2): 210–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Maelandsmo GM, Holm R, Nesland JM, *et al.*: **Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma.** *Clin Cancer Res.* 2003; **9**(9): 3383–8.
[PubMed Abstract](#)
- Bachmann IM, Straume O, Puntervoll HE, *et al.*: **Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.** *Clin Cancer Res.* 2005; **11**(24 Pt 1): 8606–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chien AJ, Moore EC, Lonsdorf AS, *et al.*: **Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.** *Proc Natl Acad Sci U S A.* 2009; **106**(4): 1193–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Biechele TL, Moon RT: **Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs.** *Methods Mol Biol.* 2008; **468**: 99–110.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Biechele TL, Moon RT: **Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs.** *Methods Mol Biol.* 2008; **468**: 99–110.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fass D, Haggarty S, Scolnick E, *et al.*: **Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder.** 2013.
[Reference Source](#)
- Willert K, Brown JD, Danenberg E, *et al.*: **Wnt proteins are lipid-modified and can act as stem cell growth factors.** *Nature.* 2003; **423**(6938): 448–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bartz SR, Zhang Z, Burchard J, *et al.*: **Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.** *Mol Cell Biol.* 2006; **26**(24): 9377–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Major MB, Roberts BS, Berndt JD, *et al.*: **New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening.** *Sci Signal.* 2008; **1**(45): ra12.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 24 July 2013

<https://doi.org/10.5256/f1000research.1476.r1185>

© 2013 Apte U. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Udayan Apte

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

1. The title is appropriate for the study.
2. The experimental design and methods are appropriate for the topic being studied.
3. The information and data provided is enough for replicating the experiment
4. The conclusions are correct but need additional data to substantiate it. In this article, the authors have identified FAM129B as a positive regulator of Wnt/beta-catenin signalling in melanoma cells. They also demonstrate that FAM129B is required for Wnt3a-induced apoptosis *in vitro*.

However; there are three important pieces of information missing that the authors should address:

- Can this effect be replicated *in vivo* in animal models?
- Does FAM129B expression correlate with beta-catenin activation and disease progression in melanoma patients?
- What is the mechanism by which FAM129B regulates Wnt signalling?

I would like the authors to do a bit more work on answering at least one of the three questions raised. They should also discuss the other two questions in the discussion section. From my standpoint it seems the easiest thing to do would be to compare FAM129 expression in various tumor samples and correlate them to Beta-catenin activation (nuclear localization) and growth pattern (tumor depth).

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Oct 2013

William Conrad, University of Washington, Seattle, USA

Dear Dr. Apte,

We appreciate your thorough reading of our manuscript, as well as the thoughtful questions that you have raised in your review. We have outlined a response to specific questions below:

1. *"Does FAM129B expression correlate with beta-catenin activation and disease progression in melanoma patients?"*

This is a very interesting question, and one which we had sought to address using previously published data from defined cohorts of melanoma patients. We analyzed the abundance of FAM129B present in three different cohorts of melanoma (Figure 5a in version 2) and observed a significantly higher abundance of FAM129B mRNA in a melanoma cohort associated with higher invasiveness and relatively lower Wnt/ β -catenin signaling. From this observation, we concluded that FAM129B abundance did not predict Wnt/ β -catenin signaling in melanoma patients. This conclusion was supported by a lack of significant correlation between levels of *FAM129B* and expression of the established Wnt/ β -catenin target gene, *AXIN2*, within this cohort (data not shown). We have included a brief discussion of these results in our revision in order to clarify the fact that we do not have data that supports a clear role of direct regulation of Wnt/ β -catenin signaling by FAM129B in melanoma patients.

2. *"Can this effect be replicated in vivo in animal models?"*

We did attempt to address this question, but despite repeated attempts we were unable to stably knock down FAM129B using lentiviral shRNA in melanoma cells. As a result, we were not able to generate cell lines that could be used to address this question in murine xenografts.

3. *"What is the mechanism by which FAM129B regulates Wnt/ β -catenin signaling?"*

Unfortunately, we have been unable to solve the specific mechanism by which FAM129B regulates Wnt/ β -catenin signaling. We had hoped that a proteomics-based approach identifying proteins that interact with FAM129B might prove informative, but to date we have not solidified any mechanistic links based on the hits identified with this strategy. While our efforts to validate this network are currently too preliminary for publication, we have (in the spirit of open access) included our FAM129B protein interaction network in its entirety in order to allow other readers to potentially gain insight and generate hypotheses regarding the role of this protein in regulating cellular signaling (Figure 5b).

Competing Interests: No competing interests were disclosed.

Reviewer Report 19 July 2013

<https://doi.org/10.5256/f1000research.1476.r1167>

© 2013 Maurice M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Madelon Maurice

Department of Cell Biology, University Medical Center Utrecht, Utrecht, The Netherlands

This report describes the identification of FAM129B as a novel regulator of Wnt/ β -catenin signalling and apoptosis in melanoma cells. The FAM129B gene was identified via integration of 3 datasets, including Wnt signaling modifiers, melanoma-associated genes and the MEK/ERK phosphoproteome. FAM129B was the only gene that overlapped with all three datasets, making it a promising candidate for regulation of both Wnt and MEK/ERK pathways in melanoma. I find this an interesting report which will provide a good starting point for further studies. Overall, the data are convincing and support the conclusions drawn. Experiments which validate FAM129B as a Wnt pathway modifier (Fig. 1-3) appear solid and display robust effects. The effects of FAM129B on apoptosis (Fig. 4b), however, are somewhat lower than expected based on the effects of FAM129B knockdown in reporter assays and on the inhibition of caspase cleavage. I feel that the authors could provide a more in-depth discussion on their findings and place them in the context of the background information provided in the introduction part;

How do the authors consider this candidate relevant for melanoma treatment?

How do the authors integrate the beneficial effects of enhanced Wnt responsiveness (this report) and the previously described enhanced tumour cell invasion (ref 20) of FAM129B expressing melanoma cells?

It would be helpful for the reader to include a model which shows how Wnt and ERK pathways modulate apoptosis in melanoma cells and where FAM129B would be placed in these events. Also in the legend of Fig. 2a it remains unclear whether endogenous levels of FAM129B are depicted.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 10 Oct 2013

William Conrad, University of Washington, Seattle, USA

Dear Dr. Maurice,

We appreciate your thorough reading of our manuscript, as well as the thoughtful questions that you have raised in your review. We have outlined a response to specific questions below:

1. *"How do the authors consider this candidate relevant for melanoma treatment?"*

It is unclear how FAM129B is relevant for melanoma treatment at this point. Our data identifies FAM129B as a regulator of Wnt/ β -catenin dependent phenotypes in

melanoma cells, while previous studies had already identified FAM129B as a downstream protein regulated by ERK/MAPK signaling. Given the importance of both of these signaling pathways in melanoma biology, we hypothesize that FAM129B could be an important regulatory nexus between Wnt/ β -catenin and ERK/MAPK signaling, although at this point we have been unable to draw a direct connection in patient tumors. Thus, at this point it is difficult to make any conclusions on the role of FAM129B's role in melanoma treatment without being overly speculative.

2. *"I feel that the authors could provide a more in-depth discussion on their findings and place them in the context of the background information provided in the introduction part"*

We have added some more content to the discussion, and we hope that these changes have improved the manuscript.

3. *"How do the authors integrate the beneficial effects of enhanced Wnt responsiveness (this report) and the previously described enhanced tumour cell invasion (ref 20) of FAM129B expressing melanoma cells?"*

You have raised a very interesting and relevant point regarding the difficulties in broadly generalizing results obtained in cultured cell systems across a disease. Our evaluation of published data (presented in this revision) also shows increased expression of FAM129B in a cohort previously defined as more invasive, and with lower activation of Wnt/ β -catenin signaling (Figure 5a). These data would suggest that in patients, the effect of FAM129B on melanoma cell invasion may supersede any effects on regulating Wnt/ β -catenin signaling.

4. In response to your helpful suggestion, we have added a model which shows how Wnt/ β -catenin and ERK/MAPK pathways modulate apoptosis in melanoma cells (Figure 5c).

5. Thank you for your careful reading of the figure legends, we have edited the legend of Figure 2a to clarify that our western blot of FAM129B is for endogenous FAM129B protein levels.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research